Search

Your search keyword '"Guariglia, Roberto"' showing total 210 results
Start Over Author "Guariglia, Roberto"
210 results on '"Guariglia, Roberto"'

2. Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients

Author

De Novellis, Danilo, Folliero, Veronica, Giudice, Valentina, Pezzullo, Luca, Sanna, Giuseppina, Fontana, Raffaele, Guariglia, Roberto, Zannella, Carla, Mettivier, Laura, Ferrara, Idalucia, Boccia, Giovanni, Buonanno, Maria Teresa, Martorelli, Maria Carmen, Luponio, Serena, Crudele, Andrea, Pagliano, Pasquale, Sessa, Anna Maria, Velino, Francesca, Langella, Maddalena, Manzin, Aldo, Galdiero, Massimiliano, Selleri, Carmine, Franci, Gianluigi, and Serio, Bianca

Published
2023
Full Text
View/download PDF

4. Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens

Author

Pezzullo Luca, Giudice Valentina, Serio Bianca, Fontana Raffaele, Guariglia Roberto, Martorelli Maria Carmen, Ferrara Idalucia, Mettivier Laura, Bruno Alessandro, Bianco Rosario, Vaccaro Emilia, Pagliano Pasquale, Montuori Nunzia, Filippelli Amelia, and Selleri Carmine

Subjects
cytomegalovirus, non-hodgkin lymphoma, chemotherapy, immunity, Medicine
Abstract

Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients’ age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age >60 years old) with newly diagnosed and relapsed/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. In particular, patients who received bendamustine plus rituximab and dexamethasone were at higher risk of CMV reactivation, especially when administered as first-line therapy and after the third course of bendamustine. In addition, patients with CMV reactivation showed a significant depression of circulating CD4+ T cell count and anti-CMV IgG levels during active infection, suggesting an impairment of immune system functions which are not able to properly face viral reactivation. Therefore, a close and early monitoring of clinical and laboratory findings might improve clinical management and outcome of non-Hodgkin lymphoma patients by preventing the development of CMV disease in a subgroup of subjects treated with bendamustine more susceptible to viral reactivation.

Published
2021
Full Text
View/download PDF

5. Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin in Patients with Hematological Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical and Matched Unrelated Donors: A Real-Life Experience

Author

Serio, Bianca, primary, Storti, Gabriella, additional, D’Addona, Matteo, additional, Santoro, Lidia, additional, Frieri, Camilla, additional, De Novellis, Danilo, additional, Marano, Luana, additional, De Santis, Giovanna, additional, Guariglia, Roberto, additional, Manfra, Ilenia, additional, Urciuoli, Eleonora, additional, Luponio, Serena, additional, Marotta, Serena, additional, Morini, Denise, additional, Rizzo, Michela, additional, Palmieri, Fausto, additional, Cantore, Nicola, additional, Giudice, Valentina, additional, Risitano, Antonio Maria, additional, and Selleri, Carmine, additional

Published
2024
Full Text
View/download PDF

6. Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens.

Author

De Novellis, Danilo, Fontana, Raffaele, Serio, Bianca, Vaccaro, Emilia, Guariglia, Roberto, Morini, Denise, Rizzo, Michela, Giudice, Valentina, and Selleri, Carmine

Subjects
MULTIPLE myeloma, VIRUS reactivation, DARATUMUMAB, TREATMENT effectiveness, MONOCLONAL antibodies
Abstract

Background: Viral reactivations are frequent in hematologial patients due to their cancer‐related and drug‐induced immunosuppressive status. Daratumumab, an anti‐CD38 monoclonal antibody, is used for multiple myeloma (MM) treatment, and causes immunosuppression by targeting CD38‐expressing normal lymphocytes. In this single‐center two‐arm real‐life experience, we evaluated incidence of cytomegalovirus (CMV) reactivation in MM patients treated with daratumumab‐based regimens as first‐ or second‐line therapy. Methods: A total of 101 consecutive MM patients were included in this study and were divided into two cohorts: daratumumab and nondaratumumab‐based (control) regimens. Patients treated with >2 lines of therapies were excluded to reduce the confounding factor of multi‐treated cases. Primary endpoint was the CMV reactivation rate. Results: CMV reactivation rate was significantly higher in the daratumumab cohort compared to control group (33% vs. 4%; p < 0.001), also with higher CMV‐DNA levels (>1000 UI/mL in 12% of cases; p < 0.05). However, only one subject developed a CMV disease with severe pneumonia, while 12% of patients were successfully treated with preemptive therapy with valganciclovir. No subjects in the control cohort required anti‐CMV agents (p = 0.02). Conclusion: Our single‐center retrospective experience showed that daratumumab might significantly increase the risk of CMV reactivation in MM, while currently underestimated and related to morbility and mortality in MM patients under treatments. However, further validation on larger and prospective clinical trials are required. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. P1531: TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON-HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE

Author

Pezzullo, Luca, primary, Giudice, Valentina, additional, D’addona, Matteo, additional, Buonanno, Maria Teresa, additional, Novellis, Danilo DE, additional, Ferrara, Idalucia, additional, Fontana, Raffaele, additional, Guariglia, Roberto, additional, Luponio, Serena, additional, Martorelli, Maria Carmela, additional, Mettivier, Laura, additional, Serio, Bianca, additional, and Selleri, Carmine, additional

Published
2023
Full Text
View/download PDF

9. P1544: IMPACT OF SARS-COV 2 INFECTION, IN TREATED NHL-B AND HD, AFTER VACCINATION AND PREVENTIVE THERAPY WITH ANTIBODIES: OUR EXPERIENCE

Author

Pezzullo, Luca, primary, Giudice, Valentina, additional, D’addona, Matteo, additional, Novellis, Danilo DE, additional, Ferrara, Idalucia, additional, Fontana, Raffaele, additional, Guariglia, Roberto, additional, Luponio, Serena, additional, Carmela Martorelli, Maria, additional, Mettivier, Laura, additional, Serio, Bianca, additional, and Selleri, Carmine, additional

Published
2023
Full Text
View/download PDF

10. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.

Author

Giudice, Valentina, Serio, Bianca, Errichiello, Santa, Ferrara, Idalucia, Galdiero, Alessandra, Bertolini, Angela, Visconti, Roberta, De Novellis, Danilo, Guariglia, Roberto, Luponio, Serena, Morini, Denise, Corte, Anna Maria Della, Sessa, Anna Maria, Verdesca, Francesco, Langella, Maddalena, Izzo, Barbara, and Selleri, Carmine

Subjects
HEMATOPOIESIS, LEUKEMIA, ACUTE myeloid leukemia, HEMATOLOGIC malignancies, PROGNOSIS
Abstract

Background: Splicing modifications, genomic instability, and hypomethylation are central mechanisms promoting myelodysplasia and acute myeloid leukemia (AML). In this real-life retrospective study, to elucidate pathophysiology of clonal hemopoiesis in hematological malignancies, we investigated clinical significance of mutations in leukemia-related genes of known pathogenetic significance and of variants of uncertain clinical significance (VUS) in a cohort of patients with MDS and AML. Methods: A total of 59 consecutive subjects diagnosed with MDS, 48 with AML, and 17 with clonal cytopenia with unknown significance were screened for somatic mutations in AML-related genes by next-generation sequencing. Results: We showed that TET2, SETBP1, ASXL1, EZH2, RUNX1, SRSF2, DNMT3A, and IDH1/2 were commonly mutated. MDS patients also showed a high genetic complexity, especially for SETBP1. Moreover, the presence of SETBP1 wild-type or two or more simultaneous VUS variants identified a subgroup of AML and MDS patients with better outcome, while the presence of single SETBP1 VUS variant was related to a worse prognosis, regardless TET2 mutational status. Conclusions: In conclusions, we linked both pathogenic and VUS variants in AML-related genes to clonal hematopoiesis; therefore, we proposed to consider those variants as prognostic markers in leukemia and myelodysplasia. However, further studies in larger prospective cohorts are required to validate our results. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study

Author

De Novellis, Danilo, primary, Fontana, Raffaele, additional, Carobene, Angela, additional, Serio, Bianca, additional, Ferrara, Idalucia, additional, Martorelli, Maria Carmen, additional, Mettivier, Laura, additional, Guariglia, Roberto, additional, Luponio, Serena, additional, Ruggiero, Immacolata, additional, D’Addona, Matteo, additional, Di Leo, Tiziana, additional, Giudice, Valentina, additional, and Selleri, Carmine, additional

Published
2022
Full Text
View/download PDF

18. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes

Author

Musto, Pellegrino, Villani, Oreste, Martorelli, Maria Carmen, Pietrantuono, Giuseppe, Guariglia, Roberto, Mansueto, Giovanna, D’Auria, Fiorella, Grieco, Vitina, Bianchino, Gabriella, Sparano, Anna, Zonno, Antonia, Lerose, Rosa, Sanpaolo, Grazia, and Falcone, Antonietta

Published
2010
Full Text
View/download PDF

19. Hemopoiesis and Immune Cell Perturbations during Venetoclax Plus Azacytidine Treatment in Acute Myeloid Leukemia

Author

Giudice, Valentina, primary, Ferrara, Idalucia, additional, Gorrese, Marisa, additional, D'Alto, Francesca, additional, Guariglia, Roberto, additional, Luponio, Serena, additional, Pezzullo, Luca, additional, Mettivier, Laura, additional, Bertolini, Angela, additional, D'Addona, Matteo, additional, De Novellis, Danilo, additional, Cuffa, Bianca, additional, Serio, Bianca, additional, and Selleri, Carmine, additional

Published
2021
Full Text
View/download PDF

20. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study

Author

Serio, Bianca, Giudice, Valentina, Guariglia, Roberto, Fontana, Raffaele, Pezzullo, Luca, Martorelli, Maria Carmen, Ferrara, Idalucia, Mettivier, Laura, D'Addona, Matteo, Vaccaro, Emilia, Langella, Maddalena, and Selleri, Carmine

Subjects
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Quinazolines, Cytomegalovirus, Humans, Transplantation, Homologous, Acetates, Antiviral Agents, Transplant Recipients
Abstract

Cytomegalovirus (CMV) reactivation is a major cause of morbidity and mortality after organ or hematopoietic stem cell transplantation (HSCT). Letermovir (LTV) is a novel antiviral agent approved for CMV prophylaxis after allogeneic transplantation. In this single-center real-world study, we evidenced the efficacy and safety of LTV for CMV prophylaxis in allogeneic HSCT recipients. A total of 133 consecutive patients who underwent autologous or allogeneic HSCT were included in the study, and a subgroup of 13 allogeneic HSCT recipients received CMV prophylaxis with LTV 240 mg/daily from day +7 to +100 (allo-LTV cohort). All patients in the allo-LTV cohort were at moderate or high risk of reactivation based on donor/recipient serology status, and 62% also received haploidentical HSCT and cyclophosphamide which further increased the CMV reactivation risk. CMV infection rate was also compared to that observed in allogeneic HSCT patients without CMV prophylaxis and autologous recipients who have the lowest reported CMV infection incidence and were used as a control cohort. In our experience, patients receiving LTV showed a significant decline in CMV reactivation incidence to similar rates described in autologous HSCT recipients (7.7% of allogeneic LTV-treated vs 68% of allogeneic recipients without prophylaxis vs 15% of autologous patients; p0.0001). The only patient in the allo-LTV cohort with CMV reactivation was a 25-year-old female with a diagnosis of very high-risk acute lymphoblastic leukemia who received a haploidentical HSCT after ex vivo T cell depletion. CMV reactivation occurred beyond LTV course, at +187 days from transplantation. In addition, we confirmed efficacy and safety of valganciclovir 450 mg/daily as pre-emptive therapy or for treatment of CMV disease in allogeneic and autologous HSCT recipients who experienced CMV reactivation even after LTV prophylaxis. However, further clinical trials in larger populations and longer follow-up are required to confirm our preliminary results.

Published
2021

23. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature

Author

Musto, Pellegrino, Scalzulli, Potito Rosario, Terruzzi, Elisabetta, Rossini, Fausto, Iacopino, Pasquale, Messina, Giuseppe, Guariglia, Roberto, Pietrantuono, Giuseppe, Villani, Oreste, D’Auria, Fiorella, Falcone, Antonietta, Sanpaolo, Grazia, Valvano, Maria Rosa, Pogliani, Enrico Maria, and Morabito, Fortunato

Published
2007
Full Text
View/download PDF

24. WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Author

Giudice, Valentina, primary, Gorrese, Marisa, additional, Vitolo, Rosa, additional, Bertolini, Angela, additional, Marcucci, Rossella, additional, Serio, Bianca, additional, Guariglia, Roberto, additional, Ferrara, Idalucia, additional, Pepe, Rita, additional, D’Alto, Francesca, additional, Izzo, Barbara, additional, Pedicini, Antonio, additional, Montuori, Nunzia, additional, Langella, Maddalena, additional, and Selleri, Carmine, additional

Published
2021
Full Text
View/download PDF

25. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia

Author

DʼArena, Giovanni, DʼAuria, Fiorella, Simeon, Vittorio, Laurenti, Luca, Deaglio, Silvia, Mansueto, Giovanna, Principe, Maria Ilaria Del, Statuto, Teodora, Pietrantuono, Giuseppe, Guariglia, Roberto, Innocenti, Idanna, Martorelli, Maria Carmen, Villani, Oreste, De Feo, Vincenzo, Poeta, Giovanni Del, and Musto, Pellegrino

Published
2012
Full Text
View/download PDF

29. Efficacy of safety and bortezomib in patients with plasma cell leukemia

Author

Musto, Pellegrino, Rossini, Fausto, Gay, Francesca, Pitini, Vincenzo, Guglielmelli, Tommasina, D'Arean, Giovanni, Ferrara, Felicetto, Filardi, Nunzio, Guariglia, Roberto, and Palumbo, Antonio

Subjects
Plasma cell diseases -- Patient outcomes, Plasma cell diseases -- Care and treatment, Leukemia -- Patient outcomes, Leukemia -- Care and treatment, Bortezomib -- Dosage and administration, Bortezomib -- Research, Health
Published
2007

30. A Rare Immune-Related Mesenteric and retroperitoneal serositis in a Multi-Refractory Hodgkin Lymphoma Patient Successfully Treated with Chylolymphostatic Surgery.

Author

D'Addona, Matteo, Pezzullo, Luca, Campisi, Corradino, Campisi, Corrado Cesare, Giudice, Valentina, Ciccone, Vincenzo, Guariglia, Roberto, Serio, Bianca, and Selleri, Carmine

Subjects
HODGKIN'S disease, TREATMENT effectiveness, PERICARDIAL effusion, MEDICAL sciences, DRUG side effects, MEDICAL societies
Published
2023
Full Text
View/download PDF

31. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Author

Musto, Pellegrino, Guariglia,Roberto, Martorelli,Maria Carmen, Lerose,Rosa, Telesca,Donatella, and Milella,Maria Rita

Subjects
Targets and Therapy [Biologics]
Abstract

Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy Abstract: Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. The current scenario of G-CSFs in Europe includes filgrastim, lenograstim, some G-CSF biosimilars, and pegfilgrastim. Recently, a novel long-acting G-CSF, lipegfilgrastim, became available. Lipegfilgrastim is a glycopegylated G-CSF, alternative to pegfilgrastim, and has shown in randomized trials, to be equivalent to pegfilgrastim in reducing the incidence of severe neutropenia and FN in patients with breast cancer receiving chemotherapy, with a similar safety profile. Furthermore, lipegfilgrastim was more effective than the placebo in reducing the incidence of severe neutropenia, its duration, and time to absolute neutrophil count recovery, in patients with non-small cell lung cancer receiving myelosuppressive therapy. Although the number of studies currently published is still limited, lipegfilgrastim seems to be a promising drug in the management of chemotherapy-induced neutropenia. Keywords: neutropenia, febrile neutropenia, granulocyte colony-stimulating factors, G-CSF, pegfilgrastim, lipegfilgrastim

Published
2016

32. Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy

Author

D'Arena, Giovanni, Musto,Pellegrino, Simeon,Vittorio, Guariglia,Roberto, Bianchino,Gabriella, Grieco,Vitina, Nozza,Milena, La Rocca,Francesco, Marziano,Gioacchino, Lalinga,Anna Vittoria, Voso,Maria Teresa, Scaravaglio,Patrizia, and Mecucci,Cristina

Subjects
OncoTargets and Therapy
Abstract

Pellegrino Musto,1 Vittorio Simeon,2 Roberto Guariglia,3 Gabriella Bianchino,4 Vitina Grieco,4 Filomena Nozza,4 Francesco La Rocca,2 Gioacchino Marziano,1 Anna Vittoria Lalinga,5 Emiliano Fabiani,6 Maria Teresa Voso,6 Patrizia Scaravaglio,7 Cristina Mecucci,8 Giovanni D'Arena31Scientific Direction, 2Laboratory of Preclinical and Translational Research, 3Unit of Hematology and Stem Cell Transplantation, 4Laboratory of Clinical Research and Advanced Diagnostics, 5Pathology Unit, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy; 6Department of Hematology, Universita Cattolica del Sacro Cuore, Rome, Italy; 7Laboratory of Internal Medicine and Hematology, S Luigi Gonzaga Hospital, Orbassano, Italy; 8Hematology and Bone Marrow Transplantation Unit, University of Perugia, Perugia, ItalyAbstract: The concomitant presence of del(5q) and JAK2V617F mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing – from a clinical, pathological, and biological point of view – for at least some of these patients as a potential distinct entity is discussed.Keywords: myelodysplastic syndromes, myeloproliferative neoplasms, lenalidomide, del(5q), JAK2, World Health Organization

Published
2014

33. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Author

Guariglia,Roberto, Martorelli,Maria Carmen, Lerose,Rosa, Telesca,Donatella, Milella,Maria Rita, Musto,Pellegrino, Guariglia,Roberto, Martorelli,Maria Carmen, Lerose,Rosa, Telesca,Donatella, Milella,Maria Rita, and Musto,Pellegrino

Abstract

Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy Abstract: Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. The current scenario of G-CSFs in Europe includes filgrastim, lenograstim, some G-CSF biosimilars, and pegfilgrastim. Recently, a novel long-acting G-CSF, lipegfilgrastim, became available. Lipegfilgrastim is a glycopegylated G-CSF, alternative to pegfilgrastim, and has shown in randomized trials, to be equivalent to pegfilgrastim in reducing the incidence of severe neutropenia and FN in patients with breast cancer receiving chemotherapy, with a similar safety profile. Furthermore, lipegfilgrastim was more effective than the placebo in reducing the incidence of severe neutropenia, its duration, and time to absolute neutrophil count recovery, in patients with non-small cell lung cancer receiving myelosuppressive therapy. Although the number of studies currently published is still limited, lipegfilgrastim seems to be a promising drug in the management of chemotherapy-induced neutropenia. Keywords: neutropenia, febrile neutropenia, granulocyte colony-stimulating factors, G-CSF, pegfilgrastim, lipegfilgrastim

Published
2016

36. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

Author

D'Arena, Giovanni, Guariglia, Roberto, La Rocca, Francesco, Trino, Stefania, Condelli, Valentina, De Martino, Laura, De Feo, Vincenzo, and Musto, Pellegrino

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

The clinical course of chronic lymphocytic leukemia (CLL) may be complicated at any time by autoimmune phenomena.The most common ones are hematologic disorders, such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Pure red cell aplasia (PRCA) and autoimmune agranulocytosis (AG) are, indeed, more rarely seen. However, they are probably underestimated due to the possible misleading presence of cytopenias secondary to leukemic bone marrow involvement or to chemotherapy cytotoxicity. The source of autoantibodies is still uncertain, despite the most convincing data are in favor of the involvement of resting normal B-cells. In general, excluding the specific treatment of underlying CLL, the managementof these complications is not different from that of idiopathic autoimmune cytopenias or of those associated to other causes. Among different therapeutic approaches, monoclonal antibody rituximab, given alone or in combination, has shown to be very effective.

Published
2013
Full Text
View/download PDF

37. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study

Author

Musto, Pellegrino, primary, Simeon, Vittorio, additional, Grossi, Alberto, additional, Gay, Francesca, additional, Bringhen, Sara, additional, Larocca, Alessandra, additional, Guariglia, Roberto, additional, Pietrantuono, Giuseppe, additional, Villani, Oreste, additional, D’Arena, Giovanni, additional, Cuomo, Carmela, additional, Musto, Clelia, additional, Morabito, Fortunato, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Zamagni, Elena, additional, Tacchetti, Paola, additional, Conticello, Concetta, additional, Milone, Giuseppe, additional, Palumbo, Antonio, additional, Cavo, Michele, additional, and Boccadoro, Mario, additional

Published
2015
Full Text
View/download PDF

38. Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy

Author

Musto,Pellegrino, Simeon,Vittorio, Guariglia,Roberto, Bianchino,Gabriella, Grieco,Vitina, Nozza,Filomena, La Rocca,Francesco, Marziano,Gioacchino, Lalinga,Anna Vittoria, Fabiani,Emiliano, Voso,Maria Teresa, Scaravaglio,Patrizia, Mecucci,Cristina, D'Arena,Giovanni, Musto,Pellegrino, Simeon,Vittorio, Guariglia,Roberto, Bianchino,Gabriella, Grieco,Vitina, Nozza,Filomena, La Rocca,Francesco, Marziano,Gioacchino, Lalinga,Anna Vittoria, Fabiani,Emiliano, Voso,Maria Teresa, Scaravaglio,Patrizia, Mecucci,Cristina, and D'Arena,Giovanni

Abstract

Pellegrino Musto,1 Vittorio Simeon,2 Roberto Guariglia,3 Gabriella Bianchino,4 Vitina Grieco,4 Filomena Nozza,4 Francesco La Rocca,2 Gioacchino Marziano,1 Anna Vittoria Lalinga,5 Emiliano Fabiani,6 Maria Teresa Voso,6 Patrizia Scaravaglio,7 Cristina Mecucci,8 Giovanni D'Arena31Scientific Direction, 2Laboratory of Preclinical and Translational Research, 3Unit of Hematology and Stem Cell Transplantation, 4Laboratory of Clinical Research and Advanced Diagnostics, 5Pathology Unit, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy; 6Department of Hematology, Universita Cattolica del Sacro Cuore, Rome, Italy; 7Laboratory of Internal Medicine and Hematology, S Luigi Gonzaga Hospital, Orbassano, Italy; 8Hematology and Bone Marrow Transplantation Unit, University of Perugia, Perugia, ItalyAbstract: The concomitant presence of del(5q) and JAK2V617F mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing – from a clinical, pathological, and biological point of view – for at least some of these patients as a potential distinct entity is discussed.Keywords: myelodysplastic syndromes, myeloproliferative neoplasms, lenalidomide, del(5q), JAK2, World Health Organization

Published
2014

39. More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection

Author

D’Arena, Giovanni, primary, Guariglia, Roberto, additional, Pietrantuono, Giuseppe, additional, Villani, Oreste, additional, Martorelli, Maria Carmen, additional, Mansueto, Giovanna, additional, Criscuolo, Clelia, additional, Pierri, Teresa, additional, Musto, Clelia, additional, and Musto, Pellegrino, additional

Published
2014
Full Text
View/download PDF

41. An Urologic Face of Chronic Lymphocytic Leukemia:Sequential Prostatic and Penis Localization

Author

D'Arena, Giovanni, primary, Guariglia, Roberto, primary, Villani, Oreste, primary, Martorelli, Maria Carmen, primary, Pietrantuono, Giuseppe, primary, Mansueto, Giovanna, primary, Patitucci, Giuseppe, primary, Imbriani, Emilio, primary, Masciandaro, Tommaso, primary, Borgia, Ludovica, primary, Vita, Giulia, primary, D'Auria, Fiorella, primary, Statuto, Teodora, primary, and Musto, Pellegrino, primary

Published
2013
Full Text
View/download PDF

42. Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Author

Musto, Pellegrino, primary, Fraticelli, Vincenzo Ludovico, additional, Mansueto, Giovanna, additional, D'Arena, Giovanni, additional, Petrilli, Maria Pia, additional, Gasbarrino, Cristiana, additional, Farina, Giuliana, additional, Guariglia, Roberto, additional, Martorelli, Maria Carmen, additional, Villani, Oreste, additional, Pietrantuono, Giuseppe, additional, Catalano, Lucio, additional, Madonna, Emanuela, additional, Nozza, Andrea, additional, Andriani, Alessandro, additional, Montefusco, Vittorio, additional, Mussetti, Alberto, additional, Lipari, Maria Grazia, additional, Ballanti, Stelvio, additional, Bongarzoni, Velia, additional, Tamiazzo, Stefania, additional, Patriarca, Francesca, additional, Vincelli, Donatella, additional, Falcone, Antonietta, additional, Derudas, Daniele, additional, Califano, Catello, additional, Zambello, Renato, additional, Mele, Giuseppe, additional, Fragasso, Alberto, additional, Baldini, Luca, additional, Palumbo, Antonio, additional, and Storti, Sergio, additional

Published
2012
Full Text
View/download PDF

43. Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia

Author

Musto, Pellegrino, primary, Simeon, Vittorio, additional, D'Arena, Giovanni, additional, Martorelli, Maria Carmen, additional, Petrucci, Maria Teresa, additional, Levi, Anna, additional, Cascavilla, Nicola, additional, Falcone, Antonietta Pia, additional, Raimondo, Francesco Di, additional, Cavalli, Maide, additional, Caravita, Tommaso, additional, Morabito, Fortunato, additional, Offidani, Massimo, additional, Filardi, Nunzio, additional, Nobile, Francesco, additional, Benevolo, Giulia, additional, Pietrantuono, Giuseppe, additional, Villani, Oreste, additional, Guariglia, Roberto, additional, Mansueto, Giovanna, additional, Lerose, Rosa, additional, Zonno, Antonia, additional, Santopietro, Valentina, additional, D'Auria, Fiorella, additional, Statuto, Teodora, additional, Todoerti, Katia, additional, Bringhen, Sara, additional, Gay, Francesca, additional, Omedè, Paola, additional, Neri, Antonino, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2012
Full Text
View/download PDF

44. Chronic Lymphocytic Leukemia After Chronic Myeloid Leukemia in the Same Patient: Two Different Genomic Events and a Common Treatment?

Author

D'Arena, Giovanni, primary, Gemei, Marica, additional, Luciano, Luigiana, additional, D'Auria, Fiorella, additional, Deaglio, Silvia, additional, Statuto, Teodora, additional, Bianchino, Gabriella, additional, Grieco, Vitina, additional, Mansueto, Giovanna, additional, Guariglia, Roberto, additional, Pietrantuono, Giuseppe, additional, Martorelli, Maria Carmen, additional, Villani, Oreste, additional, Del Vecchio, Luigi, additional, and Musto, Pellegrino, additional

Published
2012
Full Text
View/download PDF

45. A shorter time to the first treatment may be predicted by the absolute number of regulatory T‐cells in patients with Rai stage 0 chronic lymphocytic leukemia

Author

D'Arena, Giovanni, primary, D'Auria, Fiorella, additional, Simeon, Vittorio, additional, Laurenti, Luca, additional, Deaglio, Silvia, additional, Mansueto, Giovanna, additional, Del Principe, Maria Ilaria, additional, Statuto, Teodora, additional, Pietrantuono, Giuseppe, additional, Guariglia, Roberto, additional, Innocenti, Idanna, additional, Martorelli, Maria Carmen, additional, Villani, Oreste, additional, De Feo, Vincenzo, additional, Del Poeta, Giovanni, additional, and Musto, Pellegrino, additional

Published
2012
Full Text
View/download PDF

46. Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

Author

Musto, Pellegrino, primary, D'Auria, Fiorella, additional, Petrucci, Maria Teresa, additional, Levi, Anna, additional, Cascavilla, Nicola, additional, Falcone, Antonietta, additional, Raimondo, Francesco Di, additional, Cavalli, Maide, additional, Caravita, Tommaso, additional, Morabito, Fortunato, additional, Offidani, Massimo, additional, Filardi, Nunzio, additional, Nobile, Francesco, additional, Benevolo, Giulia, additional, Pietrantuono, Giuseppe, additional, Martorelli, Maria Carmen, additional, Villani, Oreste, additional, Guariglia, Roberto, additional, Mansueto, Giovanna, additional, D'Arena, Giovanni, additional, Lerose, Rosa, additional, Zonno, Antonia, additional, Zifarone, Emanuela, additional, Santopietro, Valentina, additional, Todoerti, Katia, additional, Bringhen, Sara, additional, Gay, Francesca, additional, Omedè, Paola, additional, Neri, Antonino, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2011
Full Text
View/download PDF

48. Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia

Author

Pietrantuono, Giuseppe, primary, Guariglia, Roberto, primary, Villani, Oreste, primary, Martorelli, Maria Carmen, primary, D’Auria, Fiorella, primary, Zonno, Antonia, primary, Lerose, Rosa, primary, Fioritoni, Giuseppe, primary, Zamagni, Elena, primary, Rossini, Fausto, primary, Filardi, Nunzio, primary, Pagano, Livio, primary, Musuraca, Gerardo, primary, Pitini, Vincenzo, primary, Quintini, Gerlando, primary, Falcone, Antonietta, primary, Bringhen, Sara, primary, Palumbo, Antonio, primary, and Musto, Pellegrino, primary

Published
2008
Full Text
View/download PDF

49. A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

Author

Guariglia, Roberto, primary, Luminari, Stefano, primary, De Renzo, Amalia, primary, Iannitto, Emilio, primary, Dell’Olio, Matteo, primary, Pozzi, Samantha, primary, Pierri, Teresa, primary, D’Amato, Lucia, primary, Traficante, Antonio, primary, Sacchi, Stefano, primary, and Musto, Pellegrino, primary

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results